# ClinicalTrials.gov Search Results 03/13/2021

| | NCT Number | Title | Other Names | Status | Conditions | Interventions | Characteristics | Population | Sponsor/ Collaborators | Funder Type | Dates | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02844062 | Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme<br><br>Study Documents: | Title Acronym:<br><br>Other Ids:<br>SBNK-2016-015-01 | Unknown status | •Glioblastoma Multiforme | •Biological: anti-EGFRvIII CAR T cells<br>•Drug: cyclophosphamide<br>•Drug: Fludarabine | Study Type:<br>Interventional<br><br>Phase:<br>Phase 1<br><br>Study Design:<br>•Allocation: N/A<br>•Intervention Model: Single Group Assignment<br>•Masking: None (Open Label)<br>•Primary Purpose: Treatment<br><br>Outcome Measures:<br>•Safety of infusion of autologous anti-EGFRvIII CAR T cells with cyclophosphamide and fludarabine as lymphodepleting chemotherapy in patients with recurrent glioblastoma using the NCI CTCAE V4.0 criteria.<br>•Treatment Responses Rate<br>•Overall Survival Rate<br>•Progression-free Survival Rate<br>•Persistence of CAR T cells in patients | Enrollment:<br>20<br><br>Age:<br>18 Years to 70 Years (Adult, Older Adult)<br><br>Sex:<br>All | •Beijing Sanbo Brain Hospital<br>•Marino Biotechnology Co., Ltd. | •Other<br>•Industry | Study Start:<br>July 2016<br><br>Primary Completion:<br>July 2018<br><br>Study Completion:<br>July 2019<br><br>First Posted:<br>July 26, 2016<br><br>Results First Posted:<br>No Results Posted<br><br>Last Update Posted:<br>July 26, 2016 | •Sanbo Brain Hospital Capital Medical University, Beijing, China |

| | NCT Number | Title | Other Names | Status | Conditions | Interventions | Characteristics | Population | Sponsor/ Collaborators | Funder Type | Dates | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | NCT04717999 | Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma<br>Study Documents: | Title Acronym:<br>Other Ids:<br>UBP-P02-3001-GBM | Not yet recruiting | •Recurrent Glioblastoma | •Biological: NKG2D CAR-T | Study Type:<br>Interventional<br>Phase:<br>Not Applicable<br>Study Design:<br>•Allocation: N/A<br>•Intervention Model: Single Group Assignment<br>•Masking: None (Open Label)<br>•Primary Purpose: Treatment<br>Outcome Measures:<br>•Number of Participants who experience a Dose-Limiting Toxicity (DLT)<br>•Overall Response Rate<br>•Progression-free survival | Enrollment:<br>20<br>Age:<br>20 Years to 70 Years (Adult, Older Adult)<br>Sex:<br>All | •UWELL Biopharma | •Industry | Study Start:<br>September 1, 2021<br>Primary Completion:<br>September 30, 2023<br>Study Completion:<br>December 31, 2023<br>First Posted:<br>January 22, 2021<br>Results First Posted:<br>No Results Posted<br>Last Update Posted:<br>January 22, 2021 | |
| 3 | NCT04385173 | Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma<br>Study Documents: | Title Acronym:<br>Other Ids:<br>SAHZJU-BP102 | Recruiting | •Recurrent Glioblastoma<br>•Refractory Glioblastoma | •Drug: B7-H3 CAR-T<br>•Drug: Temozolomide | Study Type:<br>Interventional<br>Phase:<br>Phase 1<br>Study Design:<br>•Allocation: N/A<br>•Intervention Model: Single Group Assignment<br>•Masking: None (Open Label)<br>•Primary Purpose: Treatment<br>Outcome Measures:<br>•Incidence and type of adverse events<br>•Maximum tolerated dose (MTD)<br>•Overall survival (OS)<br>•Progression-free survival (PFS)<br>•The pharmacokinetics (PK) of B7-H3 CAR-T<br>•Disease response (ORR, CR, PR, DOR) | Enrollment:<br>12<br>Age:<br>18 Years to 75 Years (Adult, Older Adult)<br>Sex:<br>All | •Second Affiliated Hospital, School of Medicine, Zhejiang University<br>•BoYuan RunSheng Pharma (Hangzhou) Co., Ltd. | •Other | Study Start:<br>June 1, 2020<br>Primary Completion:<br>May 1, 2022<br>Study Completion:<br>July 1, 2022<br>First Posted:<br>May 12, 2020<br>Results First Posted:<br>No Results Posted<br>Last Update Posted:<br>May 12, 2020 | •the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China |

| | NCT Number | Title | Other Names | Status | Conditions | Interventions | Characteristics | Population | Sponsor/ Collaborators | Funder Type | Dates | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 | NCT03726515 | CART-EGFRvIII + Pembrolizumab in GBM<br><br>Study Documents: | Title Acronym:<br><br>Other Ids:<br>831706, UPCC 13318 | Completed | •Glioblastoma | •Biological: CART-EGFRvIII T cells<br>•Biological: Pembrolizumab | Study Type:<br>Interventional<br><br>Phase:<br>Phase 1<br><br>Study Design:<br>•Allocation: N/A<br>•Intervention Model: Single Group Assignment<br>•Masking: None (Open Label)<br>•Primary Purpose: Treatment<br><br>Outcome Measures:<br>•Number of subjects with treatment-related adverse events, using NCI CTCAE v5.0.<br>•Overall survival Rate<br>•Progression-free survival (PFS)<br>•Objective response rate (ORR) | Enrollment:<br>7<br><br>Age:<br>18 Years and older (Adult, Older Adult)<br><br>Sex:<br>All | •University of Pennsylvania | •Other | Study Start:<br>March 11, 2019<br><br>Primary Completion:<br>February 27, 2021<br><br>Study Completion:<br>February 27, 2021<br><br>First Posted:<br>October 31, 2018<br><br>Results First Posted:<br>No Results Posted<br><br>Last Update Posted:<br>March 3, 2021 | •Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States |

| | NCT Number | Title | Other Names | Status | Conditions | Interventions | Characteristics | Population | Sponsor/ Collaborators | Funder Type | Dates | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5 | NCT04077866 | B7-H3 CAR-T for Recurrent or Refractory Glioblastoma<br><br>Study Documents: | Title Acronym:<br><br>Other Ids:<br>SAHZJU-RCT-BP102 | Recruiting | •Recurrent Glioblastoma<br>•Refractory Glioblastoma | •Drug: Temozolomide<br>•Biological: B7-H3 CAR-T | Study Type:<br>Interventional<br><br>Phase:<br>•Phase 1<br>•Phase 2<br><br>Study Design:<br>•Allocation: Randomized<br>•Intervention Model: Parallel Assignment<br>•Masking: None (Open Label)<br>•Primary Purpose: Treatment<br><br>Outcome Measures:<br>•Overall survival (OS)<br>•Incidence and type of adverse events<br>•Maximum tolerated dose (MTD)<br>•Progression-free survival (PFS)<br>•Peak Concentration (Cmax) of B7-H3 CAR-T<br>•Area under the concentration versus time curve (AUC) of B7-H3 CAR-T<br>•Disease response (ORR, CR, PR, DOR) | Enrollment:<br>40<br><br>Age:<br>18 Years to 75 Years (Adult, Older Adult)<br><br>Sex:<br>All | •Second Affiliated Hospital, School of Medicine, Zhejiang University<br>•Ningbo Yinzhou People's Hospital<br>•Huizhou Municipal Central Hospital<br>•BoYuan RunSheng Pharma (Hangzhou) Co., Ltd. | •Other | Study Start:<br>May 1, 2022<br><br>Primary Completion:<br>June 1, 2024<br><br>Study Completion:<br>July 1, 2024<br><br>First Posted:<br>September 4, 2019<br><br>Results First Posted:<br>No Results Posted<br><br>Last Update Posted:<br>May 19, 2020 | •the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China<br>•Huzhou Central Hospital, Huzhou, Zhejiang, China<br>•Ningbo Yinzhou People's Hospital, Ningbo, Zhejiang, China |

| | NCT Number | Title | Other Names | Status | Conditions | Interventions | Characteristics | Population | Sponsor/ Collaborators | Funder Type | Dates | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 | NCT04214392 | Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MPP2+ Recurrent or Progressive Glioblastoma<br><br>Study Documents: | Title Acronym:<br><br>Other Ids:<br>•19309<br>•NCI-2019-08393 | Recruiting | •Recurrent Glioblastoma<br>•Recurrent Malignant Glioma<br>•Recurrent WHO Grade II Glioma<br>•Recurrent WHO Grade III Glioma | •Biological: Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes | Study Type:<br>Interventional<br><br>Phase:<br>Phase 1<br><br>Study Design:<br>•Allocation: N/A<br>•Intervention Model: Single Group Assignment<br>•Masking: None (Open Label)<br>•Primary Purpose: Treatment<br><br>Outcome Measures:<br>•Dose limiting toxicity (DLT)<br>•Chimeric antigen receptor (CAR) T cell<br>•Endogenous T cell<br>•Cytokine levels in TCF, PB and CSF<br>•Progression free survival time<br>•Disease response<br>•Overall survival (OS)<br>•CAR T cells detected in tumor tissue<br>•Chlorotoxin-targeted antigen expression levels in tumor tissue<br>•Biomathematical modeling of tumor growth | Enrollment:<br>36<br><br>Age:<br>18 Years and older (Adult, Older Adult)<br><br>Sex:<br>All | •City of Hope Medical Center<br>•National Cancer Institute (NCI) | •Other<br>•NIH | Study Start:<br>February 26, 2020<br><br>Primary Completion:<br>February 6, 2023<br><br>Study Completion:<br>February 6, 2023<br><br>First Posted:<br>January 2, 2020<br><br>Results First Posted:<br>No Results Posted<br><br>Last Update Posted:<br>May 1, 2020 | •City of Hope Medical Center, Duarte, California, United States |

| | NCT Number | Title | Other Names | Status | Conditions | Interventions | Characteristics | Population | Sponsor/ Collaborators | Funder Type | Dates | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7 | NCT02664363 | EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma<br><br>Study Documents:<br>•Study Protocol and Statistical Analysis Plan | Title Acronym:<br>ExCeL<br><br>Other Ids:<br>Pro00069444 | Terminated | •Glioblastoma<br>•Gliosarcoma | •Biological: EGFRvIII CAR T cells | Study Type:<br>Interventional<br><br>Phase:<br>Phase 1<br><br>Study Design:<br>•Allocation: N/A<br>•Intervention Model: Single Group Assignment<br>•Masking: None (Open Label)<br>•Primary Purpose: Treatment<br><br>Outcome Measures:<br>•Maximally Tolerated Dose<br>•Number of Patients Who Experienced a Dose-limiting Toxicity (DLT) | Enrollment:<br>3<br><br>Age:<br>18 Years to 80 Years (Adult, Older Adult)<br><br>Sex:<br>All | •Gary Archer Ph.D.<br>•Duke University | •Other | Study Start:<br>February 1, 2017<br><br>Primary Completion:<br>September 25, 2018<br><br>Study Completion:<br>September 12, 2019<br><br>First Posted:<br>January 27, 2016<br><br>Results First Posted:<br>July 24, 2020<br><br>Last Update Posted:<br>July 24, 2020 | •The Preston Robert Tisch Brain Tumor Center at Duke, Durham, North Carolina, United States |
| 8 | NCT04045847 | CD147-CART Cells in Patients With Recurrent Malignant Glioma.<br><br>Study Documents: | Title Acronym:<br><br>Other Ids:<br>Chen Zhinan-2 | Recruiting | •Recurrent Glioblastoma<br>•CD147 Positive | •Biological: CD147-CART | Study Type:<br>Interventional<br><br>Phase:<br>Early Phase 1<br><br>Study Design:<br>•Allocation: N/A<br>•Intervention Model: Single Group Assignment<br>•Masking: None (Open Label)<br>•Primary Purpose: Treatment<br><br>Outcome Measures:<br>•Incidence and type of adverse events induced by CD147-CART<br>•DLT and MTD of CD147-CART cell<br>•Clinical Activity of CD147-CART cell<br>•CD147-CART detection in Peripheral Blood | Enrollment:<br>31<br><br>Age:<br>18 Years to 65 Years (Adult, Older Adult)<br><br>Sex:<br>All | •Xijing Hospital | •Other | Study Start:<br>May 30, 2019<br><br>Primary Completion:<br>October 30, 2020<br><br>Study Completion:<br>May 30, 2022<br><br>First Posted:<br>August 6, 2019<br><br>Results First Posted:<br>No Results Posted<br><br>Last Update Posted:<br>May 7, 2020 | •National Translational Science Center for Molecular Medicine & Department of Cell Biology, Xi'an, Shaanxi, China |

| | NCT Number | Title | Other Names | Status | Conditions | Interventions | Characteristics | Population | Sponsor/ Collaborators | Funder Type | Dates | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 | NCT04003649 | IL13Ralpha2-Targeted Chimeric Antigen Receptor (CAR) T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With Recurrent or Refractory Glioblastoma<br><br>Study Documents: | Title Acronym:<br><br>Other Ids:<br>•18251<br>•NCI-2018-02764<br>•R01CA236500 | Recruiting | •Recurrent Glioblastoma<br>•Refractory Glioblastoma | •Biological: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells<br>•Biological: Ipilimumab<br>•Biological: Nivolumab<br>•Other: Quality-of-Life Assessment<br>•Other: Questionnaire Administration | Study Type:<br>Interventional<br><br>Phase:<br>Phase 1<br><br>Study Design:<br>•Allocation: Randomized<br>•Intervention Model: Parallel Assignment<br>•Masking: None (Open Label)<br>•Primary Purpose: Treatment<br><br>Outcome Measures:<br>•Incidence of adverse events<br>•Dose-limiting toxicity (DLT)<br>•Feasibility (neoadjuvant therapy)<br>•Feasibility (adjuvant therapy)<br>•Survival<br>•T cell levels<br>•Cytokine levels in TCF, PB, and CSF<br>•Disease response<br>•Time to progression<br>•Overall survival (OS)<br>•and 7 more | Enrollment:<br>60<br><br>Age:<br>18 Years to 75 Years (Adult, Older Adult)<br><br>Sex:<br>All | •City of Hope Medical Center<br>•National Cancer Institute (NCI) | •Other<br>•NIH | Study Start:<br>September 26, 2019<br><br>Primary Completion:<br>December 1, 2022<br><br>Study Completion:<br>December 1, 2022<br><br>First Posted:<br>July 1, 2019<br><br>Results First Posted:<br>No Results Posted<br><br>Last Update Posted:<br>December 9, 2020 | •City of Hope Medical Center, Duarte, California, United States |

| | NCT Number | Title | Other Names | Status | Conditions | Interventions | Characteristics | Population | Sponsor/ Collaborators | Funder Type | Dates | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10 | NCT04661384 | Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma<br><br>Study Documents: | Title Acronym:<br><br>Other Ids:<br>•19497<br>•NCI-2020-06010<br>•P30CA033572 | Recruiting | •Leptomeningeal Metastases | •Biological: IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes | Study Type:<br>Interventional<br><br>Phase:<br>Phase 1<br><br>Study Design:<br>•Allocation: N/A<br>•Intervention Model: Single Group Assignment<br>•Masking: None (Open Label)<br>•Primary Purpose: Treatment<br><br>Outcome Measures:<br>•Incidence of adverse events<br>•Overall survival<br>•CAR T cell levels detected in tumor cyst fluid (TCF), peripheral blood (PB), and cerebrospinal fluid (CSF)<br>•Endogenous T cell levels detected in tumor cyst fluid (TCF), peripheral blood (PB), and cerebrospinal fluid (CSF)<br>•Cell phenotype detected in tumor cyst fluid (TCF), peripheral blood (PB), and cerebrospinal fluid (CSF)<br>•Cytokine levels in PB, TCF and CSF<br>•Disease response<br>•Time to progression<br>•CAR T and endogenous cells detected in tumor tissue<br>•IL13Raphs2 antigen expression levels in tumor tissue.<br>•Biomathematical Modeling of tumor growth<br>•Biomathematical Modeling of perfusion/diffusion | Enrollment:<br>30<br><br>Age:<br>18 Years and older (Adult, Older Adult)<br><br>Sex:<br>All | •City of Hope Medical Center<br>•National Cancer Institute (NCI) | •Other<br>•NIH | Study Start:<br>February 15, 2021<br><br>Primary Completion:<br>December 15, 2022<br><br>Study Completion:<br>December 15, 2022<br><br>First Posted:<br>December 10, 2020<br><br>Results First Posted:<br>No Results Posted<br><br>Last Update Posted:<br>January 27, 2021 | •City of Hope Medical Center, Duarte, California, United States |

| | NCT Number | Title | Other Names | Status | Conditions | Interventions | Characteristics | Population | Sponsor/ Collaborators | Funder Type | Dates | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11 | NCT02209376 | Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma<br><br>Study Documents: | Title Acronym:<br><br>Other Ids:<br>UPCC 35313, 820381 | Terminated | •Patients With Residual or Reccurent EGFRvIII+ Glioma | •Biological: CART-EGFRvIII T cells | Study Type:<br>Interventional<br><br>Phase:<br>Phase 1<br><br>Study Design:<br>•Allocation: N/A<br>•Intervention Model: Single Group Assignment<br>•Masking: None (Open Label)<br>•Primary Purpose: Treatment<br><br>Outcome Measures:<br>Number of adverse events | Enrollment:<br>11<br><br>Age:<br>18 Years and older (Adult, Older Adult)<br><br>Sex:<br>All | •University of Pennsylvania<br>•University of California, San Francisco | •Other | Study Start:<br>November 18, 2014<br><br>Primary Completion:<br>April 4, 2018<br><br>Study Completion:<br>April 4, 2018<br><br>First Posted:<br>August 5, 2014<br><br>Results First Posted:<br>No Results Posted<br><br>Last Update Posted:<br>March 5, 2019 | •UCSF, San Francisco, California, United States<br>•Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States |
| 12 | NCT02937844 | Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme<br><br>Study Documents: | Title Acronym:<br><br>Other Ids:<br>SBNK-2016-016-01 | Unknown status | •Glioblastoma Multiforme | •Biological: Anti-PD-L1 CSR T cells<br>•Drug: Cyclophosphamide<br>•Drug: Fludarabine | Study Type:<br>Interventional<br><br>Phase:<br>Phase 1<br><br>Study Design:<br>•Allocation: N/A<br>•Intervention Model: Single Group Assignment<br>•Masking: None (Open Label)<br>•Primary Purpose: Treatment<br><br>Outcome Measures:<br>•Number of Adverse Events related to CSR T cell infusion<br>•Treatment Responses Rate<br>•Overall Survival Rate<br>•Progression-free Survival Rate | Enrollment:<br>20<br><br>Age:<br>18 Years to 70 Years (Adult, Older Adult)<br><br>Sex:<br>All | •Beijing Sanbo Brain Hospital<br>•Marino Biotechnology Co., Ltd. | •Other<br>•Industry | Study Start:<br>July 2016<br><br>Primary Completion:<br>July 2018<br><br>Study Completion:<br>July 2019<br><br>First Posted:<br>October 19, 2016<br><br>Results First Posted:<br>No Results Posted<br><br>Last Update Posted:<br>October 19, 2016 | •Sanbo Brain Hospital Capital Medical University, Beijing, China |

| | NCT Number | Title | Other Names | Status | Conditions | Interventions | Characteristics | Population | Sponsor/ Collaborators | Funder Type | Dates | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13 | NCT03283631 | Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM<br><br>Study Documents: | Title Acronym:<br>INTERCEPT<br><br>Other Ids:<br>•Pro00083828<br>•5P50CA190991-03 | Suspended | •Recurrent Glioblastoma<br>•Recurrent Gliosarcoma | •Biological: EGFRvIII-CARs | Study Type:<br>Interventional<br><br>Phase:<br>Phase 1<br><br>Study Design:<br>•Allocation: N/A<br>•Intervention Model: Single Group Assignment<br>•Masking: None (Open Label)<br>•Primary Purpose: Treatment<br><br>Outcome Measures:<br>•Determination of Maximum Tolerated Dose (MTD)<br>•Assessment of T Cell trafficking within the brain tumor<br>•Assessment of T cell trafficking systemically<br>•Median survival<br>•Median progression-free survival | Enrollment:<br>24<br><br>Age:<br>18 Years and older (Adult, Older Adult)<br><br>Sex:<br>All | •Gary Archer Ph.D.<br>•National Cancer Institute (NCI)<br>•Duke Cancer Institute<br>•Duke University | •Other<br>•NIH | Study Start:<br>May 30, 2018<br><br>Primary Completion:<br>December 31, 2021<br><br>Study Completion:<br>December 31, 2022<br><br>First Posted:<br>September 14, 2017<br><br>Results First Posted:<br>No Results Posted<br><br>Last Update Posted:<br>April 22, 2020 | •Duke University Medical Center, Durham, North Carolina, United States |

| | NCT Number | Title | Other Names | Status | Conditions | Interventions | Characteristics | Population | Sponsor/ Collaborators | Funder Type | Dates | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14 | NCT03170141 | Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme<br><br>Study Documents: | Title Acronym:<br><br>Other Ids:<br>GIMI-IRB-17003 | Enrolling by invitation | •Glioblastoma Multiforme of Brain<br>•Glioblastoma Multiforme | •Biological: Antigen-specific IgT cells | Study Type:<br>Interventional<br><br>Phase:<br>Phase 1<br><br>Study Design:<br>•Allocation: N/A<br>•Intervention Model: Single Group Assignment<br>•Masking: None (Open Label)<br>•Primary Purpose: Treatment<br><br>Outcome Measures:<br>•Safety of infusion of autologous IgT cells with cyclophosphamide and fludarabine as lymphodepleting chemotherapy in patients with recurrent glioblastoma using the NCI CTCAE V4.0 criteria.<br>•Treatment response rate of recurrent glioblastoma<br>•Overall survival Rate<br>•Progression-free survival rate<br>•Persistence and proliferation of IgT cells in patients<br>•Production of specific immune check point modulatory proteins | Enrollment:<br>20<br><br>Age:<br>1 Year to 80 Years (Child, Adult, Older Adult)<br><br>Sex:<br>All | •Shenzhen Geno-Immune Medical Institute | •Other | Study Start:<br>May 31, 2019<br><br>Primary Completion:<br>August 1, 2019<br><br>Study Completion:<br>December 31, 2022<br><br>First Posted:<br>May 30, 2017<br><br>Results First Posted:<br>No Results Posted<br><br>Last Update Posted:<br>March 3, 2021 | •Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China<br>•Department of Neurosurgery, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China |

| | NCT Number | Title | Other Names | Status | Conditions | Interventions | Characteristics | Population | Sponsor/ Collaborators | Funder Type | Dates | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15 | NCT04270461 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors<br>Study Documents: | Title Acronym:<br>Other Ids:<br>JiujiangUH | Withdrawn | •Hepatocellular Carcinoma<br>•Glioblastoma<br>•Medulloblastoma<br>•Colon Cancer | •Biological: NKG2D-based CAR T-cells | Study Type:<br>Interventional<br>Phase:<br>Phase 1<br>Study Design:<br>•Allocation: N/A<br>•Intervention Model: Single Group Assignment<br>•Masking: None (Open Label)<br>•Primary Purpose: Treatment<br>Outcome Measures:<br>•Number of Participants with severe cytokine release syndrome(CRS) as a Measure of Safety and Tolerability.<br>•Copies numbers of CAR<br>•overall survival (OS)<br>•Progress Free Survival (PFS)<br>•Duration of response, (DoR) | Enrollment:<br>0<br>Age:<br>18 Years to 75 Years (Adult, Older Adult)<br>Sex:<br>All | •Jiujiang University Affiliated Hospital<br>•KAEDI | •Other | Study Start:<br>March 17, 2020<br>Primary Completion:<br>October 17, 2020<br>Study Completion:<br>October 17, 2020<br>First Posted:<br>February 17, 2020<br>Results First Posted:<br>No Results Posted<br>Last Update Posted:<br>October 22, 2020 | •Affiliated hospital of jiujiang university, Jiujiang, Jiangxi, China |
| 16 | NCT03392545 | Combination of Immunization and Radiotherapy for Malignant Gliomas (InSituVac1)<br>Study Documents: | Title Acronym:<br>InSituVac1<br>Other Ids:<br>B0011 | Recruiting | •High Grade Glioma<br>•Glioblastoma<br>•Glioma of Brainstem<br>•Glioma, Malignant | •Combination Product: Combined immune adjuvants and radiation | Study Type:<br>Interventional<br>Phase:<br>Phase 1<br>Study Design:<br>•Allocation: N/A<br>•Intervention Model: Single Group Assignment<br>•Masking: None (Open Label)<br>•Primary Purpose: Treatment<br>Outcome Measures:<br>•Incidence of Treatment-related Adverse Events<br>•Progression-free Survival<br>•Overall Survival | Enrollment:<br>30<br>Age:<br>18 Years to 65 Years (Adult, Older Adult)<br>Sex:<br>All | •Beijing Tiantan Hospital<br>•Duke University | •Other | Study Start:<br>April 1, 2018<br>Primary Completion:<br>April 1, 2020<br>Study Completion:<br>June 1, 2020<br>First Posted:<br>January 8, 2018<br>Results First Posted:<br>No Results Posted<br>Last Update Posted:<br>July 11, 2019 | •Beijing Tiantan Hospital, Beijing, Beijing, China |

| | NCT Number | Title | Other Names | Status | Conditions | Interventions | Characteristics | Population | Sponsor/ Collaborators | Funder Type | Dates | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17 | NCT01454596 | CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII<br><br>Study Documents:<br>•Study Protocol and Statistical Analysis Plan<br>•Informed Consent Form | Title Acronym:<br><br>Other Ids:<br>•110266<br>•11-C-0266 | Completed | •Malignant Glioma<br>•Glioblastoma<br>•Brain Cancer<br>•Gliosarcoma | •Biological: Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL<br>•Drug: Aldesleukin<br>•Drug: Fludarabine<br>•Drug: Cyclophosphamide | Study Type:<br>Interventional<br><br>Phase:<br>•Phase 1<br>•Phase 2<br><br>Study Design:<br>•Allocation: Non-Randomized<br>•Intervention Model: Sequential Assignment<br>•Masking: None (Open Label)<br>•Primary Purpose: Treatment<br><br>Outcome Measures:<br>•Number of Treatment Related Adverse Events<br>•Progression Free Survival<br>•Number of Patients With an Objective Response<br>•Circulating Chimeric Antigen Receptor (CAR+) Cells in Peripheral Blood at 1 Month Post Treatment<br>•Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0) | Enrollment:<br>18<br><br>Age:<br>18 Years to 70 Years (Adult, Older Adult)<br><br>Sex:<br>All | •National Cancer Institute (NCI)<br>•National Institutes of Health Clinical Center (CC) | •NIH | Study Start:<br>May 16, 2012<br><br>Primary Completion:<br>November 1, 2018<br><br>Study Completion:<br>January 17, 2019<br><br>First Posted:<br>October 19, 2011<br><br>Results First Posted:<br>August 21, 2019<br><br>Last Update Posted:<br>August 21, 2019 | •National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States |

| | NCT Number | Title | Other Names | Status | Conditions | Interventions | Characteristics | Population | Sponsor/ Collaborators | Funder Type | Dates | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18 | NCT01109095 | CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM<br><br>Study Documents: | Title Acronym:<br>HERT-GBM<br><br>Other Ids:<br>H-24487 - HERT GBM | Completed | •Glioblastoma Multiforme (GBM) | •Biological: HER.CAR CMV-specific CTLs | Study Type:<br>Interventional<br><br>Phase:<br>Phase 1<br><br>Study Design:<br>•Allocation: N/A<br>•Intervention Model: Single Group Assignment<br>•Masking: None (Open Label)<br>•Primary Purpose: Treatment<br><br>Outcome Measures:<br>•Number of subjects with dose limiting toxicity after CTL infusion<br>•Decrease in tumor after the CTL infusion<br>•Area under the growth curves (AUC) over time for T cell frequencies.<br>•Impact of gene modified CTL on CMV-specific T lymphocyte immune response | Enrollment:<br>16<br><br>Age:<br>Child, Adult, Older Adult<br><br>Sex:<br>All | •Baylor College of Medicine<br>•The Methodist Hospital System<br>•Center for Cell and Gene Therapy, Baylor College of Medicine | •Other | Study Start:<br>October 2010<br><br>Primary Completion:<br>June 2014<br><br>Study Completion:<br>March 7, 2018<br><br>First Posted:<br>April 22, 2010<br><br>Results First Posted:<br>No Results Posted<br><br>Last Update Posted:<br>April 25, 2019 | •Houston Methodist Hospital, Houston, Texas, United States<br>•Texas Children's Hospital, Houston, Texas, United States |

| | NCT Number | Title | Other Names | Status | Conditions | Interventions | Characteristics | Population | Sponsor/ Collaborators | Funder Type | Dates | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19 | NCT02208362 | Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma<br><br>Study Documents: | Title Acronym:<br><br>Other Ids:<br>•13384<br>•NCI-2014-01488<br>•P30CA033572<br>•R01FD005129 | Recruiting | •Recurrent Glioblastoma<br>•Recurrent Malignant Glioma<br>•Recurrent WHO Grade II Glioma<br>•Recurrent WHO Grade III Glioma<br>•Refractory Glioblastoma<br>•Refractory Malignant Glioma<br>•Refractory WHO Grade II Glioma<br>•Refractory WHO Grade III Glioma | •Biological: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/ MEM Cells<br>•Biological: IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes<br>•Other: Laboratory Biomarker Analysis<br>•Procedure: Magnetic Resonance Imaging<br>•Procedure: Magnetic Resonance Spectroscopic Imaging<br>•Other: Quality-of-Life Assessment | Study Type:<br>Interventional<br><br>Phase:<br>Phase 1<br><br>Study Design:<br>•Allocation: Non-Randomized<br>•Intervention Model: Parallel Assignment<br>•Masking: None (Open Label)<br>•Primary Purpose: Treatment<br><br>Outcome Measures:<br>•Incidence of grade 3 toxicity<br>•Incidence of dose limiting toxicity (DLT), graded using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0<br>•Incidence of toxicities, graded using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0 as well as the modified neurological grading system<br>•Changes in largest length of tumor<br>•Changes in cytokine levels<br>•Changes in chimeric antigen receptor (CAR) T levels<br>•Progression free survival (PFS)<br>•Disease response by the Response Assessment in Neuro-Oncology criteria<br>•Disease response (stratum 1 and 2)<br>•CAR T cell detection (stratum 1 and 2)<br>•and 6 more | Enrollment:<br>92<br><br>Age:<br>12 Years to 75 Years (Child, Adult, Older Adult)<br><br>Sex:<br>All | •City of Hope Medical Center<br>•National Cancer Institute (NCI)<br>•Food and Drug Administration (FDA) | •Other<br>•NIH<br>•U.S. Fed | Study Start:<br>May 18, 2015<br><br>Primary Completion:<br>January 18, 2022<br><br>Study Completion:<br>January 18, 2022<br><br>First Posted:<br>August 5, 2014<br><br>Results First Posted:<br>No Results Posted<br><br>Last Update Posted:<br>February 11, 2021 | •City of Hope Comprehensive Cancer Center, Duarte, California, United States |